149 related articles for article (PubMed ID: 28818446)
1. Characterization of a highly selective inhibitor of the Aurora kinases.
Ferguson FM; Doctor ZM; Chaikuad A; Sim T; Kim ND; Knapp S; Gray NS
Bioorg Med Chem Lett; 2017 Sep; 27(18):4405-4408. PubMed ID: 28818446
[TBL] [Abstract][Full Text] [Related]
2. 3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization.
Morioka M
Bioorg Med Chem Lett; 2016 Dec; 26(24):5860-5862. PubMed ID: 27884697
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitors as potential anticancer agents: Recent advances.
Pradhan T; Gupta O; Singh G; Monga V
Eur J Med Chem; 2021 Oct; 221():113495. PubMed ID: 34020340
[TBL] [Abstract][Full Text] [Related]
4. SAR156497, an exquisitely selective inhibitor of aurora kinases.
Carry JC; Clerc F; Minoux H; Schio L; Mauger J; Nair A; Parmantier E; Le Moigne R; Delorme C; Nicolas JP; Krick A; Abécassis PY; Crocq-Stuerga V; Pouzieux S; Delarbre L; Maignan S; Bertrand T; Bjergarde K; Ma N; Lachaud S; Guizani H; Lebel R; Doerflinger G; Monget S; Perron S; Gasse F; Angouillant-Boniface O; Filoche-Rommé B; Murer M; Gontier S; Prévost C; Monteiro ML; Combeau C
J Med Chem; 2015 Jan; 58(1):362-75. PubMed ID: 25369539
[TBL] [Abstract][Full Text] [Related]
5. Aurora Kinase Inhibitors in Head and Neck Cancer.
Qi G; Liu J; Mi S; Tsunematsu T; Jin S; Shao W; Liu T; Ishimaru N; Tang B; Kudo Y
Curr Top Med Chem; 2018; 18(3):199-213. PubMed ID: 29332580
[TBL] [Abstract][Full Text] [Related]
6. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.
Bo YX; Xiang R; Xu Y; Hao SY; Wang XR; Chen SW
Bioorg Med Chem; 2020 Mar; 28(5):115351. PubMed ID: 32035750
[TBL] [Abstract][Full Text] [Related]
8. SAR and evaluation of novel 5H-benzo[c][1,8]naphthyridin-6-one analogs as Aurora kinase inhibitors.
Karra S; Xiao Y; Chen X; Liu-Bujalski L; Huck B; Sutton A; Goutopoulos A; Askew B; Josephson K; Jiang X; Shutes A; Shankar V; Noonan T; Garcia-Berrios G; Dong R; Dhanabal M; Tian H; Wang Z; Clark A; Goodstal S
Bioorg Med Chem Lett; 2013 May; 23(10):3081-7. PubMed ID: 23570792
[TBL] [Abstract][Full Text] [Related]
9. Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors.
Lin SY; Chang CF; Coumar MS; Chen PY; Kuo FM; Chen CH; Li MC; Lin WH; Kuo PC; Wang SY; Li AS; Lin CY; Yang CM; Yeh TK; Song JS; Hsu JTA; Hsieh HP
Bioorg Chem; 2020 May; 98():103689. PubMed ID: 32171993
[TBL] [Abstract][Full Text] [Related]
10. A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.
Li J; Hu H; Lang Q; Zhang H; Huang Q; Wu Y; Yu L
Eur J Med Chem; 2013 Jul; 65():151-7. PubMed ID: 23707920
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
[TBL] [Abstract][Full Text] [Related]
12. Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells.
Defaux J; Antoine M; Logé C; Le Borgne M; Schuster T; Seipelt I; Aicher B; Teifel M; Günther E; Gerlach M; Marchand P
Bioorg Med Chem Lett; 2014 Aug; 24(16):3748-52. PubMed ID: 25022204
[TBL] [Abstract][Full Text] [Related]
13. A dual aurora and lim kinase inhibitor reduces glioblastoma proliferation and invasion.
Rybin MJ; Laverde-Paz MJ; Suter RK; Affer M; Ayad NG; Feng Y; Zeier Z
Bioorg Med Chem Lett; 2022 Apr; 61():128614. PubMed ID: 35151865
[TBL] [Abstract][Full Text] [Related]
14. Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer.
Dokla EME; Abdel-Aziz AK; Milik SN; Mahmoud AH; Saadeldin MK; McPhillie MJ; Minucci S; Abouzid KAM
Bioorg Chem; 2021 Dec; 117():105451. PubMed ID: 34736137
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases.
Sini P; Gürtler U; Zahn SK; Baumann C; Rudolph D; Baumgartinger R; Strauss E; Haslinger C; Tontsch-Grunt U; Waizenegger IC; Solca F; Bader G; Zoephel A; Treu M; Reiser U; Garin-Chesa P; Boehmelt G; Kraut N; Quant J; Adolf GR
Mol Cancer Ther; 2016 Oct; 15(10):2388-2398. PubMed ID: 27496137
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Discovery and Bioactivity Evaluation of Novel Aurora-A Kinase Inhibitors as Anticancer Agents via Docking-Based Comparative Intermolecular Contacts Analysis (dbCICA).
Hijjawi MS; Abutayeh RF; Taha MO
Molecules; 2020 Dec; 25(24):. PubMed ID: 33353031
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 2,4-disubstituted phthalazinones as Aurora kinase inhibitors.
Wang W; Feng X; Liu HX; Chen SW; Hui L
Bioorg Med Chem; 2018 Jul; 26(12):3217-3226. PubMed ID: 29705376
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.
Zheng YG; Wang JA; Meng L; Pei X; Zhang L; An L; Li CL; Miao YL
Eur J Med Chem; 2021 Jan; 209():112934. PubMed ID: 33109396
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of novel phenyldiazepine and pyridodiazepine based Aurora kinase inhibitors.
Tamizharasan N; Gajendran C; Kristam R; Sulochana SP; Sivanandhan D; Mullangi R; Mathivathanan L; Hallur G; Suresh P
Bioorg Chem; 2020 Jun; 99():103800. PubMed ID: 32283344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
